Published in Oncologist on January 28, 2009
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet (2014) 1.67
Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About? Curr Genomics (2010) 0.94
Bony lesions in pediatric acute leukemia: pictorial essay. Iran J Radiol (2012) 0.93
Cancer karyotypes: survival of the fittest. Front Oncol (2013) 0.90
Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr (2011) 0.89
Survival and morbidity outcomes for very low birth weight infants with Down syndrome. Pediatrics (2010) 0.87
Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report. J Med Case Rep (2011) 0.85
DNA Damage and Repair in Schizophrenia and Autism: Implications for Cancer Comorbidity and Beyond. Int J Mol Sci (2016) 0.79
Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 0.79
Syndrome-Associated Tumors by Organ System. J Pediatr Genet (2016) 0.75
Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep (2015) 0.75
Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature. Indian J Hematol Blood Transfus (2012) 0.75
SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. Childs Nerv Syst (2016) 0.75
Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget (2017) 0.75
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Down's syndrome. Lancet (2003) 5.10
Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet (2000) 3.84
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet (2002) 3.35
An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet (2006) 2.74
Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr (1999) 2.71
Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature (2008) 2.71
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood (2006) 2.58
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia (2003) 2.53
Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet (2005) 2.44
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol (2000) 2.32
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A (2006) 2.08
Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child (1957) 2.07
Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood (2003) 2.03
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol (1997) 2.02
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood (1992) 1.97
Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol (2003) 1.93
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood (2003) 1.80
Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood (2005) 1.72
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer (2007) 1.69
Natural history of GATA1 mutations in Down syndrome. Blood (2003) 1.65
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood (2008) 1.56
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res (2005) 1.53
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia (2005) 1.51
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood (2005) 1.51
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood (2001) 1.50
Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia (1998) 1.44
Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood (2003) 1.40
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood (2003) 1.37
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood (2003) 1.34
Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood (2007) 1.30
Immunology of Down syndrome: a review. Am J Med Genet Suppl (1990) 1.30
Down syndrome and acute lymphoblastic leukaemia. Br J Haematol (2006) 1.25
Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med (1996) 1.24
Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol (2005) 1.22
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood (2005) 1.20
Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer (2006) 1.19
Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. Leukemia (2005) 1.18
Acute leukemias in children with Down syndrome. Pediatr Clin North Am (2008) 1.16
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol (2008) 1.15
Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer (2005) 1.14
High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet (2001) 1.13
Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res (1998) 1.13
Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review. Pediatr Blood Cancer (2005) 1.12
Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr (1987) 1.10
Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr (1987) 1.09
Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer (2005) 1.09
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res (2004) 1.07
Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol (2007) 1.03
Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res (1994) 1.02
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol (2004) 1.02
Leucocyte function in Down's syndrome and acute leukaemia. Lancet (1972) 1.01
Child and maternal household chemical exposure and the risk of acute leukemia in children with Down's syndrome: a report from the Children's Oncology Group. Am J Epidemiol (2006) 0.98
JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia (2007) 0.96
Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group. Pediatrics (2006) 0.96
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol (2006) 0.95
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia (2000) 0.94
Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child (2001) 0.93
Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child (1999) 0.93
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol (1993) 0.92
Altered cellular immune functions in patients with Down's syndrome. Am J Dis Child (1981) 0.92
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood (2007) 0.90
Periconceptional vitamin useand leukemia risk in children with Down syndrome: a Children's Oncology Group study. Cancer (2005) 0.90
Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol (2006) 0.89
Environmental factors contributing to the development of childhood leukemia in children with Down's syndrome. Leukemia (2003) 0.89
Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children's Oncology Group. Cancer (2007) 0.88
Magnetic fields and acute leukemia in children with Down syndrome. Epidemiology (2007) 0.87
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia (2007) 0.87
Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet (1986) 0.87
Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia (2004) 0.87
DNA damage and repair in children with Down's syndrome. Mutat Res (2007) 0.86
Childhood and maternal infections and risk of acute leukaemia in children with Down syndrome: a report from the Children's Oncology Group. Br J Cancer (2004) 0.85
Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer (2007) 0.84
Vincristine pharmacokinetics in children with Down syndrome. Pediatr Blood Cancer (2009) 0.84
Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res (2008) 0.81
Humoral immunodeficiencies in Down syndrome: serum IgG subclass and antibody response to hepatitis B vaccine. Am J Med Genet Suppl (1990) 0.80
Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl (1990) 0.78
Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study. Paediatr Perinat Epidemiol (2008) 0.76
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer (2007) 1.73
Improving pediatric chemotherapy safety through voluntary incident reporting: lessons from the field. J Pediatr Oncol Nurs (2004) 1.47
Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma (2009) 1.45
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.29
Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer (2011) 1.15
Circumstances surrounding the deaths of hospitalized children: opportunities for pediatric palliative care. Pediatrics (2004) 1.14
Executive function, coping, and behavior in survivors of childhood acute lymphocytic leukemia. J Pediatr Psychol (2008) 1.13
Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer (2008) 1.10
Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer (2005) 1.09
Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol (2006) 1.07
Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses. Pediatr Blood Cancer (2010) 1.00
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood (2013) 0.99
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol (2003) 0.98
Updates on histiocytic disorders. Pediatr Blood Cancer (2014) 0.94
Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatr Blood Cancer (2013) 0.92
Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol (2013) 0.90
Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatr Blood Cancer (2010) 0.88
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol (2009) 0.84
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer (2010) 0.82
Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein. Clin Infect Dis (2003) 0.81
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2006) 0.80
A chemotherapy incident reporting and improvement system. Jt Comm J Qual Saf (2003) 0.79
A novel t(2;20)(q35;p12) in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet (2004) 0.79
High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children. Pediatr Blood Cancer (2010) 0.77
Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer (2007) 0.76
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma. Pediatr Blood Cancer (2009) 0.75